Literature DB >> 32188766

Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults.

Tengfei Guo1, Susan M Landau2, William J Jagust2.   

Abstract

OBJECTIVE: To examine the feasibility of using cross-sectional PET to identify cognitive decliners among β-amyloid (Aβ)-negative cognitively normal (CN) elderly adults.
METHODS: We determined the highest Aβ-affected region by ranking baseline and accumulation rates of florbetapir-PET regions in 355 CN elderly adults using 18F-florbetapir-PET from the Alzheimer's Disease Neuroimaging Initiative (ADNI). The banks of the superior temporal sulcus (BANKSSTS) were found as the highest Aβ-affected region, and Aβ positivity in this region was defined as above the lowest boundary of BANKSSTS standardized uptake value ratio of Aβ+ (ADNI-defined COMPOSITE region) CN individuals. The entire CN cohort was divided as follows: stage 0, BANKSSTS-COMPOSITE-; stage 1, BANKSSTS+COMPOSITE-; and stage 2, BANKSSTS+COMPOSITE+. Linear mixed-effect (LME) models investigated subsequent longitudinal cognitive change, and 18F-flortaucipir (FTP)-PET was measured 4.8 ± 1.6 years later to track tau deposition.
RESULTS: LME analysis revealed that individuals in stage 1 (n = 64) and stage 2 (n = 99) showed 2.5 (p < 0.05) and 4.8 (p < 0.001) times faster memory decline, respectively, than those in stage 0 (n = 191) over >4 years of mean follow-up. Compared to stage 0, both stage 1 (p < 0.05) and stage 2 (p < 0.001) predicted higher FTP in entorhinal cortex.
CONCLUSIONS: Nominally Aβ- CN individuals with high Aβ in BANKSSTS are at increased risk of cognitive decline, probably showing an earlier stage of Aβ deposition. Our findings may help elucidate the association between brain Aβ accumulation and cognition in Aβ- CN cohorts. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in elderly CN individuals those with high PET-identified superior temporal sulcus Aβ burden have an increased risk of cognitive decline.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32188766      PMCID: PMC7251521          DOI: 10.1212/WNL.0000000000009216

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   11.800


  48 in total

1.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

2.  Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.

Authors:  Robert H Pietrzak; Yen Ying Lim; Alexander Neumeister; David Ames; Kathryn A Ellis; Karra Harrington; Nicola T Lautenschlager; Carolina Restrepo; Ralph N Martins; Colin L Masters; Victor L Villemagne; Christopher C Rowe; Paul Maruff
Journal:  JAMA Psychiatry       Date:  2015-03       Impact factor: 21.596

3.  Subthreshold Amyloid Predicts Tau Deposition in Aging.

Authors:  Stephanie L Leal; Samuel N Lockhart; Anne Maass; Rachel K Bell; William J Jagust
Journal:  J Neurosci       Date:  2018-04-23       Impact factor: 6.167

4.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

5.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.

Authors:  Michael C Donohue; Reisa A Sperling; Ronald Petersen; Chung-Kai Sun; Michael W Weiner; Paul S Aisen
Journal:  JAMA       Date:  2017-06-13       Impact factor: 56.272

6.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease.

Authors:  T Gómez-Isla; R Hollister; H West; S Mui; J H Growdon; R C Petersen; J E Parisi; B T Hyman
Journal:  Ann Neurol       Date:  1997-01       Impact factor: 10.422

7.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

Authors:  Michael C Donohue; Reisa A Sperling; David P Salmon; Dorene M Rentz; Rema Raman; Ronald G Thomas; Michael Weiner; Paul S Aisen
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

8.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Authors:  Stephen Salloway; Reisa Sperling; Nick C Fox; Kaj Blennow; William Klunk; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Steven Ferris; Marcel Reichert; Nzeera Ketter; Bijan Nejadnik; Volkmar Guenzler; Maja Miloslavsky; Daniel Wang; Yuan Lu; Julia Lull; Iulia Cristina Tudor; Enchi Liu; Michael Grundman; Eric Yuen; Ronald Black; H Robert Brashear
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

9.  Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.

Authors:  Brian A Gordon; Tyler M Blazey; Yi Su; Amrita Hari-Raj; Aylin Dincer; Shaney Flores; Jon Christensen; Eric McDade; Guoqiao Wang; Chengjie Xiong; Nigel J Cairns; Jason Hassenstab; Daniel S Marcus; Anne M Fagan; Clifford R Jack; Russ C Hornbeck; Katrina L Paumier; Beau M Ances; Sarah B Berman; Adam M Brickman; David M Cash; Jasmeer P Chhatwal; Stephen Correia; Stefan Förster; Nick C Fox; Neill R Graff-Radford; Christian la Fougère; Johannes Levin; Colin L Masters; Martin N Rossor; Stephen Salloway; Andrew J Saykin; Peter R Schofield; Paul M Thompson; Michael M Weiner; David M Holtzman; Marcus E Raichle; John C Morris; Randall J Bateman; Tammie L S Benzinger
Journal:  Lancet Neurol       Date:  2018-02-01       Impact factor: 44.182

10.  Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults.

Authors:  Michelle E Farrell; Xi Chen; Melissa M Rundle; Micaela Y Chan; Gagan S Wig; Denise C Park
Journal:  Neurology       Date:  2018-10-10       Impact factor: 9.910

View more
  14 in total

1.  Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment.

Authors:  Jiehui Jiang; Can Sheng; Guanqun Chen; Chunhua Liu; Shichen Jin; Lanlan Li; Xueyan Jiang; Ying Han
Journal:  Geroscience       Date:  2022-05-18       Impact factor: 7.713

2.  Genome-wide association study identifies APOE locus influencing plasma p-tau181 levels.

Authors:  Yu-Yuan Huang; Yu-Xiang Yang; Hui-Fu Wang; Xue-Ning Shen; Lan Tan; Jin-Tai Yu
Journal:  J Hum Genet       Date:  2022-03-07       Impact factor: 3.755

Review 3.  Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.

Authors:  Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2021-09-28       Impact factor: 16.655

4.  β-Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.

Authors:  Chenyang Jiang; Qingyong Wang; Siwei Xie; Zhicheng Chen; Liping Fu; Qiyu Peng; Ying Liang; Hongbo Guo; Tengfei Guo
Journal:  Brain Commun       Date:  2022-03-31

5.  Prediction of 7-year's conversion from subjective cognitive decline to mild cognitive impairment.

Authors:  Ling Yue; Dan Hu; Han Zhang; Junhao Wen; Ye Wu; Wei Li; Lin Sun; Xia Li; Jinghua Wang; Guanjun Li; Tao Wang; Dinggang Shen; Shifu Xiao
Journal:  Hum Brain Mapp       Date:  2020-10-08       Impact factor: 5.038

6.  Early detection of amyloid load using 18F-florbetaben PET.

Authors:  Santiago Bullich; Núria Roé-Vellvé; Marta Marquié; Susan M Landau; Henryk Barthel; Victor L Villemagne; Ángela Sanabria; Juan Pablo Tartari; Oscar Sotolongo-Grau; Vincent Doré; Norman Koglin; Andre Müller; Audrey Perrotin; Aleksandar Jovalekic; Susan De Santi; Lluís Tárraga; Andrew W Stephens; Christopher C Rowe; Osama Sabri; John P Seibyl; Mercè Boada
Journal:  Alzheimers Res Ther       Date:  2021-03-27       Impact factor: 6.982

7.  The APOE gene cluster responds to air pollution factors in mice with coordinated expression of genes that differs by age in humans.

Authors:  Amin Haghani; Max Thorwald; Todd E Morgan; Caleb E Finch
Journal:  Alzheimers Dement       Date:  2020-11-20       Impact factor: 21.566

8.  Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease.

Authors:  Shi-Dong Chen; Yu-Yuan Huang; Xue-Ning Shen; Yu Guo; Lan Tan; Qiang Dong; Jin-Tai Yu
Journal:  Transl Psychiatry       Date:  2021-06-12       Impact factor: 6.222

9.  Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer's disease.

Authors:  Tengfei Guo; Deniz Korman; Renaud La Joie; Leslie M Shaw; John Q Trojanowski; William J Jagust; Susan M Landau
Journal:  Alzheimers Res Ther       Date:  2020-08-15       Impact factor: 6.982

10.  Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease.

Authors:  Julia Pfeil; Merle C Hoenig; Elena Doering; Thilo van Eimeren; Alexander Drzezga; Gérard N Bischof
Journal:  Neurobiol Aging       Date:  2021-06-21       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.